Alba Moratiel-Pellitero, María Zapata-García, Marta Gascón-Ruiz, Andrea Sesma, Elisa Quílez, Ariel Ramirez-Labrada, Luis Martínez-Lostao, María Pilar Domingo, Patricia Esteban, Alfonso Yubero, Raquel Barbero-Herranz, Ana Moreno-Blanco, José Ramón Paño, Rodrigo Lastra, Julián Pardo, Dolores Isla, Rosa Del Campo, Eva Gálvez
Immune checkpoint inhibitors have been proposed as the standard treatment for different stages of non-small-cell lung cancer in multiple indications. Not all patients benefit from these treatments, however, and certain patients develop immune-related adverse events. Although the search for predictors of response to these drugs is a major field of research, these issues have yet to be resolved. It has been postulated that microbiota could play a relevant role in conditioning the response to cancer treatments; however, the human factor of intestinal permeability also needs to be considered as it is closely related to the regulation of host-microbiota interaction...
March 13, 2024: Cancers